RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
Acrylamide (AM), used in the manufacture of polyacrylamide and grouting agents, is produced during the cooking of foods. Workplace exposure to AM can occur through the dermal and inhalation routes. The objective of this study was to define the kinetics of elimination of AM and its metabolites following oral and dermal administration. This is the second part of a study in which metabolites and hemoglobin adducts of AM were determined in people (Fennell et al., Toxicol. Sci. 2005, 447-459). (1,2,3-(13)C3)AM was administered in an aqueous solution orally (single dose of 0.5, 1.0, or 3.0 mg/kg) or dermally (3 daily doses of 3.0 mg/kg) to sterile male volunteers. Urine samples were collected at 0-2, 2-4, 4-8, 8-16 and 16-24 h following administration orally, or at 0-2, 2-4, 4-8, 8-16 and 16-24 h following each of 3 daily dermal doses. (13)C3-AM and its metabolites in urine, (13)C3-glycidamide, (13)C3-N-acetyl-S-(3-amino-3-oxopropyl)cysteine and its S-oxide, and (13)C3-N-acetyl-S-(3-amino-2-hydroxy-3-oxopropyl)cysteine were quantitated using LC-MS/MS. The recovered urinary metabolites accounted for 45.6, 49.9, and 39.9 % of a 0.5, 1.0, and 3.0 mg/kg oral dose (0-24 h), respectively, and for 4.5 % of the dose after 3 mg/kg administered daily for 3 days dermally (0-4 days). These results indicate that after oral administration AM is rapidly absorbed and eliminated. The half life estimated for elimination of AM in urine was 3.1-3.5 h. After dermal administration, AM uptake is slow. This study indicated that skin provides a barrier that slows the absorption of AM, and results in limited systemic availability following dermal exposure to AM
